113 related articles for article (PubMed ID: 17915148)
1. [Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound].
Lasave LI; Abizaid AA; Paiva e Maia J; de Ribamar Costa J; Feres F; Mattos LA; Abizaid AS; Siqueira DA; Tanajura LF; Staico R; Beraldo de Andrade P; Braga SN; Sousa AG; Sousa JE
Rev Esp Cardiol; 2007 Sep; 60(9):923-31. PubMed ID: 17915148
[TBL] [Abstract][Full Text] [Related]
2. Comparison of zotarolimus-eluting stents with sirolimus-eluting and paclitaxel-eluting stents: intimal hyperplasia and vascular changes assessed by volumetric intravascular ultrasound analysis.
Kang SJ; Mintz GS; Park DW; Lee SW; Kim YH; Lee CW; Han KH; Kim JJ; Park SW; Park SJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):139-45. PubMed ID: 21364151
[TBL] [Abstract][Full Text] [Related]
3. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting.
Hong YJ; Jeong MH; Lim SY; Lee SR; Kim KH; Sohn IS; Park HW; Kim JH; Kim W; Ahn Y; Cho JG; Park JC; Kang JC
Circ J; 2005 Dec; 69(12):1477-83. PubMed ID: 16308495
[TBL] [Abstract][Full Text] [Related]
4. Preprocedural inflammation does not affect neointimal hyperplasia following everolimus-eluting stent implantation.
Nakatani D; Ako J; Yamasaki M; Shimohama T; Hasegawa T; Otake H; Waseda K; Tsujino I; Sakurai R; Koo BK; Chang H; Yock PG; Sudhir K; Pierson W; Stone GW; Saito S; Honda Y; Fitzgerald PJ
J Invasive Cardiol; 2009 Dec; 21(12):613-7. PubMed ID: 19966361
[TBL] [Abstract][Full Text] [Related]
5. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
[TBL] [Abstract][Full Text] [Related]
6. Comparison of inflammatory markers for the prediction of neointimal hyperplasia after drug-eluting stent implantation.
Kang WC; Il Moon C; Lee K; Han SH; Suh SY; Moon J; Shin MS; Ahn T; Shin EK
Coron Artery Dis; 2011 Dec; 22(8):526-32. PubMed ID: 21909023
[TBL] [Abstract][Full Text] [Related]
7. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
[TBL] [Abstract][Full Text] [Related]
8. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis.
Dussaillant GR; Mintz GS; Pichard AD; Kent KM; Satler LF; Popma JJ; Wong SC; Leon MB
J Am Coll Cardiol; 1995 Sep; 26(3):720-4. PubMed ID: 7642865
[TBL] [Abstract][Full Text] [Related]
9. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III.
Miyazawa A; Ako J; Hongo Y; Hur SH; Tsujino I; Courtney BK; Hassan AH; Kandzari DE; Honda Y; Fitzgerald PJ;
Am Heart J; 2008 Jan; 155(1):108-13. PubMed ID: 18082499
[TBL] [Abstract][Full Text] [Related]
10. The effect of shear stress on neointimal response following sirolimus- and paclitaxel-eluting stent implantation compared with bare-metal stents in humans.
Papafaklis MI; Bourantas CV; Theodorakis PE; Katsouras CS; Naka KK; Fotiadis DI; Michalis LK
JACC Cardiovasc Interv; 2010 Nov; 3(11):1181-9. PubMed ID: 21087755
[TBL] [Abstract][Full Text] [Related]
11. Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study.
Eshtehardi P; Cook S; Wandel S; Räber L; Wenaweser P; Togni M; Vogel R; Garachemani A; Eberli FR; Lüscher TF; Jüni P; Hess OM; Meier B; Windecker S
EuroIntervention; 2010 Sep; 6(4):467-74. PubMed ID: 20884434
[TBL] [Abstract][Full Text] [Related]
12. Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial.
Jensen LO; Maeng M; Thayssen P; Christiansen EH; Hansen KN; Galloe A; Kelbaek H; Lassen JF; Thuesen L
Eur Heart J; 2008 Nov; 29(22):2733-41. PubMed ID: 18832385
[TBL] [Abstract][Full Text] [Related]
13. Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial.
Jensen LO; Maeng M; Thayssen P; Villadsen A; Krusell L; Botker HE; Pedersen KE; Aaroe J; Christiansen EH; Vesterlund T; Hansen KN; Ravkilde J; Tilsted HH; Lassen JF; Thuesen L
EuroIntervention; 2011 Jul; 7(3):323-31. PubMed ID: 21729834
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of coronary remodeling after sirolimus-eluting stent implantation by serial three-dimensional intravascular ultrasound.
Degertekin M; Regar E; Tanabe K; Lemos P; Lee CH; Smits P; de Feyter P; Bruining N; Sousa E; Abizaid A; Ligthart J; Serruys PW
Am J Cardiol; 2003 May; 91(9):1046-50. PubMed ID: 12714144
[TBL] [Abstract][Full Text] [Related]
15. Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials.
Waseda K; Hasegawa T; Ako J; Honda Y; Grube E; Whitbourn R; Ormiston J; O'Shaughnessy CD; Henry TD; Overlie P; Schwartz LB; Sudhir K; Chevalier B; Gray WA; Yeung AC; Fitzgerald PJ;
Circ J; 2010 Nov; 74(11):2334-9. PubMed ID: 20890052
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial).
Hirohata A; Morino Y; Ako J; Sakurai R; Buchbinder M; Caputo RP; Karas SP; Mishkel GJ; Mooney MR; O'shaughnessy CD; Raizner AE; Wilensky RL; Williams DO; Wong SC; Yock PG; Honda Y; Moses JW; Fitzgerald PJ;
Am J Cardiol; 2006 Dec; 98(11):1464-7. PubMed ID: 17126651
[TBL] [Abstract][Full Text] [Related]
17. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.
Degertekin M; Serruys PW; Foley DP; Tanabe K; Regar E; Vos J; Smits PC; van der Giessen WJ; van den Brand M; de Feyter P; Popma JJ
Circulation; 2002 Sep; 106(13):1610-3. PubMed ID: 12270850
[TBL] [Abstract][Full Text] [Related]
18. Optimal stent-sizing with intravascular ultrasound contributes to complete neointimal coverage after sirolimus-eluting stent implantation assessed by angioscopy.
Sera F; Awata M; Uematsu M; Kotani J; Nanto S; Nagata S
JACC Cardiovasc Interv; 2009 Oct; 2(10):989-94. PubMed ID: 19850260
[TBL] [Abstract][Full Text] [Related]
19. Comparison of neointimal hyperplasia with drug-eluting stents versus bare metal stents in patients undergoing intracoronary bone-marrow mononuclear cell transplantation following acute myocardial infarction.
Villa A; Arnold R; Sánchez PL; Gimeno F; Ramos B; Cantero T; Fernández ME; Sanz R; Gutiérrez O; Mota P; García-Frade J; San Román JA; Fernández-Avilés F;
Am J Cardiol; 2009 Jun; 103(12):1651-6. PubMed ID: 19539071
[TBL] [Abstract][Full Text] [Related]
20. Angiographic and volumetric intravascular ultrasound comparison between direct sirolimus-eluting stent implantation versus predilation.
Muñoz JS; Abizaid A; Albertal M; Mintz GS; Graebin R; Feres F; Staico R; Mattos LA; Tanajura LF; Abizaid AS; Sousa A; Sousa JE
Am J Cardiol; 2004 Jun; 93(12):1522-5. PubMed ID: 15194025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
